We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

1mfp

From Proteopedia

(Difference between revisions)
Jump to: navigation, search

OCA (Talk | contribs)
(New page: 200px<br /><applet load="1mfp" size="450" color="white" frame="true" align="right" spinBox="true" caption="1mfp, resolution 2.33&Aring;" /> '''E. coli Enoyl Reduct...)
Next diff →

Revision as of 19:16, 20 November 2007


1mfp, resolution 2.33Å

Drag the structure with the mouse to rotate

E. coli Enoyl Reductase in complex with NAD and SB611113

Overview

Bacterial enoyl-ACP reductase (FabI) is responsible for catalyzing the, final step of bacterial fatty acid biosynthesis and is an attractive, target for the development of novel antibacterial agents. Previously we, reported the development of FabI inhibitor 4 with narrow spectrum, antimicrobial activity and in vivo efficacy against Staphylococcus aureus, via intraperitoneal (ip) administration. Through iterative medicinal, chemistry aided by X-ray crystal structure analysis, a new series of, inhibitors has been developed with greatly increased potency against, FabI-containing organisms. Several of these new inhibitors have potent, antibacterial activity against multidrug resistant strains of S. aureus, and compound 30 demonstrates exceptional oral (po) in vivo efficacy in a, S. aureus infection model in rats. While optimizing FabI inhibitory, activity, compounds 29 and 30 were identified as having low micromolar, FabK inhibitory activity, thereby increasing the antimicrobial spectrum of, these compounds to include the FabK-containing pathogens Streptococcus, pneumoniae and Enterococcus faecalis. The results described herein support, the hypothesis that bacterial enoyl-ACP reductases are valid targets for, antibacterial agents.

About this Structure

1MFP is a Single protein structure of sequence from Escherichia coli with SO4, NAD and IDN as ligands. Active as [acyl-carrier-protein_reductase_(NADH) Enoyl-[acyl-carrier-protein] reductase (NADH)], with EC number 1.3.1.9 Full crystallographic information is available from OCA.

Reference

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK., Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF, J Med Chem. 2003 Apr 24;46(9):1627-35. PMID:12699381 [[Category: Enoyl-[acyl-carrier-protein] reductase (NADH)]]

Page seeded by OCA on Tue Nov 20 21:23:14 2007

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools